Estimation of treatment effects in early phase randomized clinical trials involving multiple data sources for external control.

IF 1.2 4区 医学 Q4 PHARMACOLOGY & PHARMACY
Heiko Götte, Marietta Kirchner, Meinhard Kieser
{"title":"Estimation of treatment effects in early phase randomized clinical trials involving multiple data sources for external control.","authors":"Heiko Götte, Marietta Kirchner, Meinhard Kieser","doi":"10.1080/10543406.2025.2512984","DOIUrl":null,"url":null,"abstract":"<p><p>Augmented randomized clinical trials are a valuable design option for early phase clinical trials. The addition of external controls could, on the one hand, increase precision in treatment effect estimates or reduce the number of required control patients for a randomized trial but may, on the other hand, introduce bias. We build on previous work on augmented trials with one external control data source in time-to-event settings and extend it to multiple control data sources. In a comprehensive simulation study, we evaluate existing and novel analysis options mainly based on Bayesian hierarchical models as well as propensity score analysis. Different sources of bias are investigated including population (observable and unobservable confounders), data collection (assessment schedule, real-world vs. clinical trial data), and time trend as well as different types of data like individual patient data (with or without baseline covariates) or summary data. Our simulation study provides recommendations in terms of choice of estimation method as well as choice of data sources. Explicit incorporation of the above-mentioned sources of bias in a simulation study is relevant as the magnitude of deviation from the ideal setting has a significant impact on all investigated estimation methods.</p>","PeriodicalId":54870,"journal":{"name":"Journal of Biopharmaceutical Statistics","volume":" ","pages":"1-19"},"PeriodicalIF":1.2000,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Biopharmaceutical Statistics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10543406.2025.2512984","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Augmented randomized clinical trials are a valuable design option for early phase clinical trials. The addition of external controls could, on the one hand, increase precision in treatment effect estimates or reduce the number of required control patients for a randomized trial but may, on the other hand, introduce bias. We build on previous work on augmented trials with one external control data source in time-to-event settings and extend it to multiple control data sources. In a comprehensive simulation study, we evaluate existing and novel analysis options mainly based on Bayesian hierarchical models as well as propensity score analysis. Different sources of bias are investigated including population (observable and unobservable confounders), data collection (assessment schedule, real-world vs. clinical trial data), and time trend as well as different types of data like individual patient data (with or without baseline covariates) or summary data. Our simulation study provides recommendations in terms of choice of estimation method as well as choice of data sources. Explicit incorporation of the above-mentioned sources of bias in a simulation study is relevant as the magnitude of deviation from the ideal setting has a significant impact on all investigated estimation methods.

涉及多个外部控制数据源的早期随机临床试验的治疗效果评估。
增强随机临床试验是早期临床试验的一种有价值的设计选择。一方面,外部对照的增加可以提高治疗效果估计的准确性,或减少随机试验所需的对照患者数量,但另一方面,可能会引入偏倚。我们以之前的工作为基础,在时间到事件设置中使用一个外部控制数据源进行增强试验,并将其扩展到多个控制数据源。在一项全面的模拟研究中,我们主要基于贝叶斯层次模型和倾向评分分析来评估现有的和新的分析选项。研究了不同的偏倚来源,包括人群(可观察和不可观察混杂因素)、数据收集(评估时间表、真实世界与临床试验数据)、时间趋势以及不同类型的数据,如个体患者数据(有或没有基线协变量)或汇总数据。我们的模拟研究在估计方法的选择和数据源的选择方面提供了建议。在模拟研究中明确纳入上述偏差来源是相关的,因为偏离理想设置的大小对所有研究的估计方法都有重大影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Biopharmaceutical Statistics
Journal of Biopharmaceutical Statistics 医学-统计学与概率论
CiteScore
2.50
自引率
18.20%
发文量
71
审稿时长
6-12 weeks
期刊介绍: The Journal of Biopharmaceutical Statistics, a rapid publication journal, discusses quality applications of statistics in biopharmaceutical research and development. Now publishing six times per year, it includes expositions of statistical methodology with immediate applicability to biopharmaceutical research in the form of full-length and short manuscripts, review articles, selected/invited conference papers, short articles, and letters to the editor. Addressing timely and provocative topics important to the biostatistical profession, the journal covers: Drug, device, and biological research and development; Drug screening and drug design; Assessment of pharmacological activity; Pharmaceutical formulation and scale-up; Preclinical safety assessment; Bioavailability, bioequivalence, and pharmacokinetics; Phase, I, II, and III clinical development including complex innovative designs; Premarket approval assessment of clinical safety; Postmarketing surveillance; Big data and artificial intelligence and applications.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信